Phathom Pharmaceuticals Inc (PHAT) - Total Liabilities
Based on the latest financial reports, Phathom Pharmaceuticals Inc (PHAT) has total liabilities worth $662.82 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore PHAT net asset momentum to track the company's year-over-year net asset growth rate.
Phathom Pharmaceuticals Inc - Total Liabilities Trend (2018–2024)
This chart illustrates how Phathom Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data.
Phathom Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Phathom Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jiangsu Baichuan HighTech New Materials Co Ltd
SHE:002455
|
China | CN¥9.52 Billion |
|
Hubeiyichang Transportation Group Co Ltd
SHE:002627
|
China | CN¥589.26 Million |
|
PNC Infratech Limited
NSE:PNCINFRA
|
India | Rs71.55 Billion |
|
GuangDong Rifeng Electric Cable Co Ltd
SHE:002953
|
China | CN¥1.80 Billion |
|
Beijing Bayi Space LCD Technology Co Ltd
SHG:688181
|
China | CN¥1.10 Billion |
|
indie Semiconductor Inc
NASDAQ:INDI
|
USA | $520.61 Million |
|
Velocity Financial Llc
NYSE:VEL
|
USA | $6.32 Billion |
|
Prima Marine Public Company Limited
BK:PRM
|
Thailand | ฿12.13 Billion |
Liability Composition Analysis (2018–2024)
This chart breaks down Phathom Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Phathom Pharmaceuticals Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.23 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.57 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.76 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Phathom Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Phathom Pharmaceuticals Inc (2018–2024)
The table below shows the annual total liabilities of Phathom Pharmaceuticals Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $631.90 Million | +29.86% |
| 2023-12-31 | $486.60 Million | +103.07% |
| 2022-12-31 | $239.62 Million | +104.33% |
| 2021-12-31 | $117.28 Million | +16.30% |
| 2020-12-31 | $100.84 Million | +245.07% |
| 2019-12-31 | $29.22 Million | +1235.60% |
| 2018-12-31 | $2.19 Million | -- |
About Phathom Pharmaceuticals Inc
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical t… Read more